Study S001917

Incretin-based Therapy in Early Diagnosed Type 1 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02908087
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 13
Start: 2016-03
Primary completion: 2021-05
Lead sponsor: University of Oulu
Conditions: Type 1 Diabetes
Interventions: DRUG:Victoza® (liraglutide); DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2014-004760-37; OTHER_GRANT:3-SRA-2014-301-M-R; OTHER:U1111-1177-0661; NIH:2014

Registered primary outcomes

Serum C-peptide AUC [From baseline to 26 and 52 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011383	INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA). Kero J, Diabetic medicine : a journal of the British Diabetic Association	2022	Protocol	PMID 35797241 DOI	cites ClinicalTrials.gov:NCT02908087; registry reference DERIVED:35797241